IP Library › Patent Application 10581169
Patent Application
App. No. 10/581,169

Liposome

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/581,169
Abstract

According to the present invention, a liposome encapsulating a water-soluble substance in an internal cavity of the liposome and having a liposome particle size of 300 nm or less can be easily prepared.

Claims (21)

1 . A liposome encapsulating a water-soluble substance in an internal cavity thereof, which has a particle size of 300 nm or less and contains a triglycerol.

2 . The liposome according to claim 1 , which has a particle size of 200 nm or less.

3 . The liposome according to claim 1 , wherein an encapsulation rate of the water-soluble compound in the internal cavity is 60% or higher.

4 . The liposome according to claim 1 , wherein an encapsulation rate of the water-soluble compound in the internal cavity is 70% or higher.

5 . The liposome according to claim 1 , wherein the water-soluble substance is a water-soluble low molecular weight compound, a protein, a nucleic acid, a polysaccharide, and/or an indicator.

6 . The liposome according to claim 1 , wherein the water-soluble substance is a water-soluble low molecular weight compound and a polysaccharide.

7 . The liposome according to claim 1 , wherein the water-soluble substance is a water-soluble low molecular weight compound.

8 . The liposome according to claim 5 , wherein the water-soluble low molecular weight compound is nedaplatin, cisplatin, carboplatin, gemcitabine, or Ara-C.

9 . The liposome according to claim 5 , wherein the polysaccharide is a chitosan derivative, or a polysaccharide having carboxyl group.

10 . The liposome according to claim 9 , wherein the polysaccharide having carboxyl group is carboxymethylcellulose, hyaluronic acid, chondroitin, or chondroitin sulfate.

11 . The liposome according to claim 1 , wherein the triglycerol is triolein.

12 . The liposome according to claim 1 , which contains a ligand and/or a water-soluble synthetic polymer.

13 . The liposome according to claim 1 , which contains a ligand.

14 . The liposome according to claim 12 , wherein the ligand binds to a target cell or a target molecule.

15 . The liposome according to claim 12 , wherein the ligand is an antibody or an antibody fragment.

16 . The liposome according to claim 12 , wherein the water-soluble synthetic polymer is selected from the group consisting of polyalkylene glycol, polylactic acid, polyglycolic acid, polyvinylpyrrolidone, and a copolymer of vinylpyrrolidone and maleic anhydride.

17 . The liposome according to claim 12 , wherein the water-soluble synthetic polymer is polyalkylene glycol.

18 . The liposome according to claim 16 , wherein the polyalkylene glycol is polyethylene glycol.

19 . The liposome according to claim 12 , wherein the ligand and/or the water-soluble synthetic polymer binds only to an external surface of the liposome.

20 . A pharmaceutical composition containing the liposome according to claim 1 .

21 . An agent for diagnosis and/or therapeutic treatment of a cancer, which comprises the liposome according to claim 1.

Assignments (2)
CHANGE OF NAME Recorded Apr 17, 2008
From: MITSUBISHI PHARMA CORPORATION
To: MITSUBISHI TANABE PHARMA CORPORATION
Reel/Frame 020838/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2007
From: TAGAWA, TOSHIAKI; UEDA, MANAMI
To: MITSUBISHI PHARMA CORPORATION
Reel/Frame 019187/0651 →